Mar 15, 2023 / 06:35PM GMT
Carter Lewis Gould - Barclays Bank PLC, Research Division - Senior Analyst
Okay. Good afternoon, and welcome to Day 2 of the Barclays Global Healthcare Conference. My name is Carter Gould, senior biopharma analyst here at Barclays, and I'm pleased to welcome Merck to the stage.
Merck has been one of our top-ranked names for a bit here and certainly came -- coming off a pretty stellar 2022, followed that up with a solid start to 2023 with PAH data, which we're going to touch on.
Joining us from the company, President of Merck Human Health, Jannie Oosthuizen, as well as Peter Dannenbaum from the IR team. Peter, Jannie, thank you very much for joining us today.
Jannie Oosthuizen - Merck & Co., Inc. - Senior VP & President Merck U.S. Human Health
Well, thank you for having us.
Carter Lewis Gould - Barclays Bank PLC, Research Division - Senior Analyst
So we can hop into Q&A unless you wanted to make any opening comments.
Jannie Oosthuizen - Merck & Co., Inc.
Merck & Co Inc at Barclays Global Healthcare Conference Transcript
Jan 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers